Share repurchase programs often lead to a positive short-term impact on a company's stock price. This is due to the reduction in the number of shares available in the market, which can increase the earnings per share (EPS) and often leads to increased investor confidence. Given that Aurinia Pharmaceuticals Inc. has received regulatory approval to proceed with its share repurchase program, it is likely that the company's stock price will experience a positive impact in the short term.